Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEAM study of TG02 in newly diagnosed elderly or relapsed adult glioblastoma/anaplastic astrocytoma
NL-OMON50615Phase 1Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zotiraciclib in glioblastoma (GBM) and anaplastic astrocytoma (AA) (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Maximum tolerated dose of TG02 plus radiotherapy, Maximum tolerated dose of TG02 plus temozolomide and 1 more. Started Sep 2018; status: active, not recruiting.
02
Drugs
zotiraciclib
03
Conditions
glioblastoma (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NL-OMON50615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50615.